Provider Locator

VIVITROL Provider Locator Loading...

If you're searching for a licensed Healthcare Provider in the United States, our Provider Locator can help. You can search by zip code or the city and state. Or if you know the physician's name, just enter his or her name.

You may also be interested in the VIVITROL Value Program, which offers up to $500 per month for 13 months of co-pay assistance for eligible patients.

Zip:

OR

City:
AND
State:

Search Radius:5102550 miles

First Name:

Last Name:

Terms of Use

The Provider Locator is compiled and published by Alkermes, Inc. as a reference source of demographic and professional information on individual licensed healthcare providers in the United States who have experience in the treatment of alcohol dependence. The Provider Locator is searchable by zip code or by city and state. Healthcare providers' enrollment and participation in the Provider Locator is voluntary and free of charge and, along with the provider-specific information in the Provider Locator, is based solely on healthcare provider responses. The Provider Locator is provided by Alkermes for use by the medical and addiction treatment communities, potential patients and/or their families in finding information on, and locating, healthcare providers for the treatment of alcohol dependence. Alkermes is not responsible for, and the Provider Locator is not intended as a tool for, verifying the credentials, expertise, abilities or quality of care of any healthcare provider included in the Provider Locator. Inclusion in the Provider Locator does not imply referral, recommendation or endorsement nor does omission in the Provider Locator imply Alkermes' disapproval. We recommend that, before scheduling an appointment to see any healthcare provider, you research the credentials of the healthcare provider and satisfy yourself that the healthcare provider provides the quality of care desired. You are prohibited from using, downloading, republishing, selling, duplicating, or "scraping" for commercial or any other purpose whatsoever, the Provider Locator or any of the data listings or other information contained therein, in whole or in part, in any medium whatsoever. The information from the Provider Locator is provided on an "AS-IS" basis. Alkermes disclaim all warranties, either express or implied, including but not limited to the implied warranties of merchantability and fitness for particular purpose. Without limiting the foregoing, Alkermes does not warrant or represent that the Provider Locator or any part thereof is accurate or complete. You assume full responsibility for the communications with any healthcare provider you contact through the Provider Locator. Alkermes shall in no event be liable to you or to anyone for any decision made or action taken by you in the reliance on information.

I agree to the Terms of Use

» Go back to Search » Print

Once you've found a licensed Healthcare Provider, you may also be interested in the VIVITROL Value Program, which offers up to $500 per month for 13 months of co-pay assistance for eligible patients.

If you would like more information on alcohol dependence and treatment options, please talk with your doctor or healthcare provider.

INDICATION1

VIVITROL® is indicated for the treatment of alcohol dependence in patients who are able to abstain from alcohol in an outpatient setting prior to initiation of treatment with VIVITROL.

Patients should not be actively drinking at the time of initial VIVITROL administration.

Treatment with VIVITROL should be part of a comprehensive management program that includes psychosocial support.

IMPORTANT SAFETY INFORMATION FOR VIVITROL1

VIVITROL is contraindicated in patients receiving opioid analgesics or with current physiologic opioid dependence, patients in acute opiate withdrawal, any individual who has failed the naloxone challenge test or has a positive urine screen for opioids, or in patients who have previously exhibited hypersensitivity to naltrexone PLG, carboxymethylcellulose or any other components of the diluent.

VIVITROL patients must be opioid free for a minimum of 7-10 days before treatment. Attempts to overcome opioid blockade due to VIVITROL may result in a fatal overdose. In prior opioid users, use of opioids after discontinuing VIVITROL may result in a fatal overdose because patients may be more sensitive to lower doses of opioids. Patients requiring reversal of the VIVITROL blockade for pain management should be monitored by appropriately trained personnel in a setting equipped for cardiopulmonary resuscitation.

Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses

Naltrexone is contraindicated in acute hepatitis or liver failure, and its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects.

The margin of separation between the apparently safe dose of naltrexone and the dose causing hepatic injury appears to be only five-fold or less. VIVITROL does not appear to be a hepatotoxin at the recommended doses.

Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Use of VIVITROL should be discontinued in the event of symptoms and/or signs of acute hepatitis.

VIVITROL is administered as a gluteal intramuscular injection. Inadvertent subcutaneous injection of VIVITROL may increase the likelihood of severe injection site reactions. VIVITROL must be injected using the customized needle provided in the carton. Because needle length may not be adequate due to body habitus, each patient should be assessed prior to each injection to assure that needle length is adequate for intramuscular administration. VIVITROL injection site reactions may be followed by pain, tenderness, induration, swelling, erythema, bruising or pruritus; however, in some cases injection site reactions may be very severe. Injection site reactions not improving may require prompt medical attention, including in some cases surgical intervention.

Consider the diagnosis of eosinophilic pneumonia if patients develop progressive dyspnea and hypoxemia. In an emergency situation in patients receiving VIVITROL, suggestions for pain management include regional analgesia or use of non-opioid analgesics. Alcohol dependent patients, including those taking VIVITROL, should be monitored for the development of depression or suicidal thoughts. Caution is recommended in administering VIVITROL to patients with moderate to severe renal impairment.

The most common adverse events associated with VIVITROL in clinical trials were nausea, vomiting, headache, dizziness, asthenic conditions and injection site reactions.

Please see VIVITROL Full Prescribing Information, including box warning by clicking on the link at the bottom of this page.